Molecular epidemiological analysis and risk factors for acquisition of carbapenemase-producing


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
2019
Historique:
received: 17 04 2019
accepted: 15 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 26 6 2020
Statut: epublish

Résumé

To clarify the molecular epidemiology of carbapenem-resistant Using clinical CREC isolates detected in a Japanese university hospital over 4 years, carbapenemase production was screened with phenotypic methods. Carbapenemase genes were analysed by PCR and sequencing. Molecular epidemiological analyses were conducted with repetitive extragenic palindromic (REP)-PCR and multilocus sequence typing (MLST). CRECs were identified to the subspecies level by Thirty-nine CRECs including 20 CPECs carrying A longer hospital stay, presence of a urinary catheter, and intubation are risk factors for CPEC acquisition. In addition to horizontal transmission of genetically indistinguishable CPECs, IncHI2A plasmid carrying

Sections du résumé

Background
To clarify the molecular epidemiology of carbapenem-resistant
Methods
Using clinical CREC isolates detected in a Japanese university hospital over 4 years, carbapenemase production was screened with phenotypic methods. Carbapenemase genes were analysed by PCR and sequencing. Molecular epidemiological analyses were conducted with repetitive extragenic palindromic (REP)-PCR and multilocus sequence typing (MLST). CRECs were identified to the subspecies level by
Results
Thirty-nine CRECs including 20 CPECs carrying
Conclusions
A longer hospital stay, presence of a urinary catheter, and intubation are risk factors for CPEC acquisition. In addition to horizontal transmission of genetically indistinguishable CPECs, IncHI2A plasmid carrying

Identifiants

pubmed: 31367347
doi: 10.1186/s13756-019-0578-3
pii: 578
pmc: PMC6657070
doi:

Substances chimiques

Bacterial Proteins 0
Chaperonin 60 0
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Emerg Infect Dis. 2018 Jun;24(6):1010-1019
pubmed: 29774858
J Clin Microbiol. 2003 Dec;41(12):5407-13
pubmed: 14662918
Expert Rev Anti Infect Ther. 2016;14(1):95-108
pubmed: 26535959
Clin Microbiol Infect. 2014 Sep;20(9):821-30
pubmed: 24930781
Bioinformatics. 2016 Jul 15;32(14):2103-10
pubmed: 27153593
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
J Clin Microbiol. 2017 Aug;55(8):2321-2333
pubmed: 28381609
mBio. 2014 Oct 07;5(5):e01918-14
pubmed: 25293762
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Clin Microbiol. 2010 Nov;48(11):3979-89
pubmed: 20861340
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038269
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311089
Appl Environ Microbiol. 2003 Sep;69(9):5306-18
pubmed: 12957918
Clin Infect Dis. 2011 Jul 1;53(1):60-7
pubmed: 21653305
Clin Infect Dis. 2016 Jun 1;62(11):1423-35
pubmed: 26936670
PLoS One. 2013 Jun 11;8(6):e66358
pubmed: 23776664
J Med Microbiol. 2013 Mar;62(Pt 3):446-50
pubmed: 23161765
Emerg Infect Dis. 2018 Aug;24(8):1505-1515
pubmed: 30014838
Clin Infect Dis. 2004 Jul 1;39(1):55-60
pubmed: 15206053
Antimicrob Agents Chemother. 2014 Jun;58(6):3441-50
pubmed: 24709261
Clin Infect Dis. 2017 Feb 1;64(3):257-264
pubmed: 28013264
Antimicrob Agents Chemother. 2011 Nov;55(11):5143-9
pubmed: 21876060
J Infect Chemother. 2018 Dec;24(12):1013-1015
pubmed: 29941275
PLoS One. 2015 Apr 13;10(4):e0119317
pubmed: 25867189
Curr Infect Dis Rep. 2018 Aug 20;20(10):42
pubmed: 30128678
mBio. 2016 Dec 13;7(6):
pubmed: 27965456
J Antimicrob Chemother. 2016 Aug;71(8):2147-57
pubmed: 27118781

Auteurs

Nobuyuki Tetsuka (N)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.
2Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi Japan.

Aki Hirabayashi (A)

3Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Akane Matsumoto (A)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.

Keisuke Oka (K)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.
2Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi Japan.

Yuki Hara (Y)

2Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi Japan.
4Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi Japan.

Hiroshi Morioka (H)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.

Mitsutaka Iguchi (M)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.

Yuka Tomita (Y)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.

Masato Suzuki (M)

3Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Keigo Shibayama (K)

5Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

Tetsuya Yagi (T)

1Department of Infectious Diseases, Nagoya University Hospital, 65 Tsurumai, Nagoya, Aichi 466-0065 Japan.
2Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH